Phase 3 results demonstrate safety and efficacy profile of Invokana (canagliflozin) as add-on therapy for type 2 diabetes in adults

Janssen Research & Development, LLC (Janssen) have announced results from a new 52-week analysis of Phase 3 results showing INVOKANA® (canagliflozin) provided substantial improvements in glycemic control in patients with type 2 diabetes who are inadequately controlled on metformin and a sulfonylurea, two of the most commonly used antihyperglycemic therapies. These results are among a total of 12 abstracts for canagliflozin being presented at the 49th European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Spain...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news